Get the Stockscreener App
9.24
9.74%
0.82
After Hours:
9.41
0.17
+1.84%
Transcode Therapeutics Inc stock is traded at $9.24, with a volume of 6,516.
It is up +9.74% in the last 24 hours and down -35.29% over the past month.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
See More
Previous Close:
$8.42
Open:
$8.57
24h Volume:
6,516
Relative Volume:
0.05
Market Cap:
$7.70M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.0347
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
-2.04%
1M Performance:
-35.29%
6M Performance:
-4.82%
1Y Performance:
-97.14%
1-Day Range:
$8.57
$9.24
1-Week Range:
$8.41
$9.85
52-Week Range:
$6.1478
$468.44
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
9.24 | 7.72M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Real time breakdown of TransCode Therapeutics Inc. stock performanceProfit Target & Step-by-Step Trade Execution Guides - newser.com
Using Python tools to backtest TransCode Therapeutics Inc. strategiesEarnings Recap Summary & Consistent Return Investment Signals - newser.com
Why retail investors favor TransCode Therapeutics Inc. stock2025 Market Overview & Reliable Volume Spike Alerts - newser.com
Market reaction to TransCode Therapeutics Inc.’s recent newsEarnings Growth Summary & Accurate Entry/Exit Alerts - newser.com
Is TransCode Therapeutics Inc. stock resilient to inflationInflation Watch & Daily Oversold Bounce Ideas - newser.com
Can TransCode Therapeutics Inc. stock deliver strong Q4 earnings2025 Momentum Check & Technical Pattern Recognition Alerts - newser.com
TransCode Therapeutics Inc. recovery potential after sell offWeekly Stock Report & Free High Return Stock Watch Alerts - newser.com
Is TransCode Therapeutics Inc. stock oversold or undervaluedTrade Exit Report & Safe Capital Growth Tips - newser.com
How TransCode Therapeutics Inc. stock reacts to job market dataEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com
Can TransCode Therapeutics Inc. stock weather global recession2025 Retail Activity & AI Forecasted Stock Moves - newser.com
Why TransCode Therapeutics Inc. stock could be next big winnerPortfolio Performance Report & Verified Chart Pattern Signals - newser.com
TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside - MSN
Chegg, Inc. Common Stock (NY: CHGG - Markets Financial Content
What MACD and RSI say about TransCode Therapeutics Inc.2025 AllTime Highs & Accurate Trade Setup Notifications - newser.com
What technical models suggest about TransCode Therapeutics Inc.’s comebackJuly 2025 Weekly Recap & Fast Momentum Entry Tips - newser.com
Is a relief rally coming for TransCode Therapeutics Inc. holdersJuly 2025 Gainers & Pattern Based Trade Signal System - newser.com
What’s the recovery path for long term holders of TransCode Therapeutics Inc.Trade Entry Summary & Scalable Portfolio Growth Ideas - newser.com
Why TransCode Therapeutics Inc. stock is considered a top pickQuarterly Earnings Summary & Community Supported Trade Ideas - newser.com
Sentiment Watch: Will TransCode Therapeutics Inc. stock benefit from AI adoptionTreasury Yields & Stock Portfolio Risk Management - Fundação Cultural do Pará
Can swing trading help recover from TransCode Therapeutics Inc. lossesWeekly Investment Report & Weekly Top Gainers Alerts - newser.com
Will TransCode Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Retail & Daily Growth Stock Tips - Fundação Cultural do Pará
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):